<![CDATA[BayNews - Bayer Press-Server]]> http://presse.bayer.de/baynews/baynews.nsf Thu, 17 May 12 03:12:43 +0200 en-en TIMETOWEB Web Content Management System 60 Not intended for U.S. and UK media - 48th Annual Meeting of the American Society of Clinical Oncology (ASCO): -- Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012 -- First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Sessionhttp://presse.bayer.de/baynews/baynews.nsf/ID/FAEFDBBF3C402425C1257A00003DE54C?OpenDocumentWed, 16 May 12 14:00:00 +0200 LEED Platinum for EcoCommercial Building in India -- Bayer building tops global sustainability rankinghttp://presse.bayer.de/baynews/baynews.nsf/ID/C0D8AC08A555CAFEC1257A000032F21E?OpenDocumentWed, 16 May 12 12:00:00 +0200 Bayer MaterialScience and adidas develop the official soccer ball of the Euro 2012 -- Doing the tango at the stadium -- New model is fast, robust and precise / High-performance materials usedhttp://presse.bayer.de/baynews/baynews.nsf/ID/2ED51A0EB3ACD1A6C12579FF004C2F3B?OpenDocumentWed, 16 May 12 10:00:00 +0200 Over 25 years of successful collaboration between adidas and Bayer MaterialScience -- A tango for the “ball season” -- Polyurethanes improve the flight properties of the European championship “Tango 12” soccer ballhttp://presse.bayer.de/baynews/baynews.nsf/ID/3E0FD58C438CF9B1C12579FF004A4485?OpenDocumentWed, 16 May 12 10:00:00 +0200 Investment into development capabilities for power generation from renewable sources: -- Bayer MaterialScience to establish global wind energy competence center in Denmark -- Pooling expertise in research and developmenthttp://presse.bayer.de/baynews/baynews.nsf/ID/D796CF41FE66A69AC12579FB0028069B?OpenDocumentFri, 11 May 12 11:00:00 +0200 Award from the Bayer Cares Foundation for innovative health projects -- &#x201C;Lebenstagebuch&#x201C; wins Aspirin Social Award 2012 -- Berlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: &#x201C;Innovative social initiatives with valuable contributions to health care&#x201C;http://presse.bayer.de/baynews/baynews.nsf/ID/B78031A3749C5ADCC12579F9004F6C89?OpenDocumentThu, 10 May 12 12:10:00 +0200 Not intended for U.S. and UK media -- Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndromehttp://presse.bayer.de/baynews/baynews.nsf/ID/49F0D65AA66D8053C12579F900297581?OpenDocumentWed, 9 May 12 15:00:00 +0200 Greater energy efficiency and safety in road traffic -- Bayer MaterialScience develops sustainable solutions for future mobility conceptshttp://presse.bayer.de/baynews/baynews.nsf/ID/4EF8F41B2697A426C12579F7002BDBE9?OpenDocumentTue, 8 May 12 10:00:00 +0200 Not intended for U.S. and UK media: -- Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE -- Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)http://presse.bayer.de/baynews/baynews.nsf/ID/6D0FE78A106685B8C12579F000490B8E?OpenDocumentWed, 2 May 12 15:00:00 +0200 Video of the speech given by Dr. Marijn Dekkers, Chairman of the Board of Management of Bayer AGhttp://presse.bayer.de/baynews/baynews.nsf/ID/8D4A0EC4CE2C537EC12579EC006F74D0?OpenDocumentFri, 27 Apr 12 10:00:00 +0200